Elevation Oncology's ADCs target CLDN18.2 and HER3, with EO-3021 showing promising Phase 1 results and a $6.6 billion TAM in gastric and pancreatic cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback